Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sesame oral immunotherapy with omalizumab for sesame anaphylaxis
IRCT20181002041210N1Phase 2Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of omalizumab in Sesame Allergy, sponsored by Iran University of Medical Sciences. Primary endpoint: Desensitization. Started Sep 2018; status: completed.
02
Drugs
omalizumab
03
Conditions
Sesame Allergy
Beyond the preview
Go deeper on IRCT20181002041210N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181002041210N1.